期刊文献+

p21和p27在肿瘤发生机制中的作用与耐药性 被引量:4

Role of p21 and p27 in carcinogenesis and drug resistance
原文传递
导出
摘要 人类肿瘤的发生是由于细胞生长和死亡的不平衡导致的.控制这个平衡的关键是调节细胞周期的蛋白.目前发现的与密切调节细胞周期特定阶段效应分子包括细胞周期蛋白,细胞周期蛋白依赖性激酶(cyclin-dependent kinases CDKs)和CDK抑制因子.G1期检测点的CDK抑制因子-p21(CDKN1 A)和p27(CDKN1 B)影响许多恶性肿瘤的发生发展.越来越多的证据表明p21或p27功能的缺失可以促进耐药.而另外一些实验证明p21和p27能促进肿瘤的发生发展.在本文中,我们将讨论这两个CDK抑制因子的功能,在肿瘤发生机制以及在耐药性中的作用. Human cancers arise from an imbalance of cell growth and cell death.Critical factors that control the balance are those regulate the cell cycle.Several molecular effectors have been identified to be able to regulate specific phases of the cell cycle,including cyclins,cyclin-dependent kinases (CDKs) and CDK inhibitors.Notably,deficiency of two G1-checkpoint CDK inhibitors-p21 (CDKN1A) and p27 (CDKN1B)-has been implicated to be correlated with initiation or progression of many human malignancies or cancer cells drug-resistance.However,contradict reports also suggested that p21 and p27 could promote tumor progression.Here,we summarized the historic and recent studies on these two CDK inhibitors,including their identification as well as their roles in carcinogenesis and drug resistance.
出处 《国际外科学杂志》 2014年第7期494-498,共5页 International Journal of Surgery
关键词 周期素依赖激酶抑制剂p21 周期素依赖激酶抑制剂P27 抗药性 肿瘤 Cyclin-dependent kinase inhibitor p21 Cyclin-dependent kinase inhibitor p27 Drug resistance,neoplasm
  • 相关文献

参考文献32

  • 1Evans T,Rosenthal ET,Youngblom J,et al.Cyclin:a protein specified by maternal mRNA iu sea urchin eggs that is destroyed at each cleavage division[J].Cell,1983,33(2):389-396.
  • 2Motokura T,Bloom T,Kim HG,et al.A novel cyclin encoded by a bcll-linked candidate oncogene[J].Nature,1991,350(6318):512-515.
  • 3Nurse P,Thuriaux P.Regulatory genes controlling mitosis in the fission yeast Schizosaccharomyces pombe[J].Genetics,1980,96(3):627-637.
  • 4Doree M,Peaucellier G,Picard A.Activity of the maturation-promoting factor and the extent of protein phosphorylation oscillate simultaneously during meiotic maturation of starfish oocytes[J].Dev Biol,1983,99(2):489-501.
  • 5Withers DA,Harvey RC,Faust JB,et al.Characterization of a candidate bcl-1 gene[J].Mol Cell Biol,1991,11 (10):4846-4853.
  • 6Xiong Y,Zhang H,Beach D.D type cyclins associate with muhiple protein kinases and the DNA replication and repair factor PCNA[J].Cell,1992,71(3):505-514.
  • 7Westbrook TF,Nguyen DX,Thrash BR.E7 abolishes raf-induced arrest via mislocalization of p21 (Cip1)[J].Mol Cell Biol,2002,22(20):7041-7052.
  • 8el-Deiry WS,Tokino T,Velculescu VE,et al.WAF1,a potential mediator of p53 tumor suppression[J].Cell,1993,75 (4):817-825.
  • 9Harper JW,Adami GR,Wei N,et al.The p21 Cdk-interacting protein Cipl is a potent inhibitor of GI cyclin-dependent kinases[J].Cell,1993,75(4):805-816.
  • 10Gu Y,Turck CW,Morgan DO.Inhibition of CDK2 activity in vivo by an associated 20K regulatou subunit[J].Nature,1993,366 (6456):707-710.

同被引文献78

  • 1高燕,林莉萍,丁健.细胞周期调控的研究进展[J].生命科学,2005,17(4):318-322. 被引量:60
  • 2王卫东,陈正堂.Bcl-2/Bax比率与细胞“命运”[J].中国肿瘤生物治疗杂志,2007,14(4):393-396. 被引量:163
  • 3Chiang KC, Yeh CN, Hsu JT, Yeh TS, Jan YY, Wu CT, Chen HY, Jwo SC, Takano M, Kittaka A, Juang HH, Chen TC. Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo. Cell Cycle 2013; 12: 1316-1325.
  • 4Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014; 159: 80-93.
  • 5Kennel KA, Drake MT. Vitamin D in the cancer patient. Curr Opin Support Palliat Care 2013; 7: 272-277.
  • 6Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, Rager H, Virtamo J, Albanes D. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res 2012; 72: 1190-1198.
  • 7Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014; 14: 342-357.
  • 8Chiang KC, Yeh CN, Hsu JT, Jan YY, Chen LW, Kuo SF, Takano M, Kittaka A, Chen TC, Chen WT, Pang JH, Yeh TS, Juang HH. The vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cells. Cancer Lett 2014; 354: 235-244.
  • 9Zhu X, Yi F, Chen P, Chen L, Zhang X, Cao C, Tan W. 5-Aza-2'-Deoxycytidine and CDDP Synergistically Induce Apoptosis in Renal Carcinoma Cells via Enhancing the APAF-1 Activity. Clin Lab 2015; 61: 1821-1830.
  • 10Chen TC, Chien CC, Wu MS, Chen YC. Evodiamine from Evodia rutaecarpa induces apoptosis via activation of JNK and PERK in human ovarian cancer cells. Phytomedicine 2016; 23: 68-78.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部